Kornimate/medical-research-clean huggingface dataset:
intelligent hypertension intervention study

Conditions: To Explore Whether the Application of Intelligent Hypertension Management System Can Effectively Reduce Blood Pressure in Hypertensive Patients

Summary: to explore whether the application of intelligent hypertension management system can effectively reduce blood pressure in hypertensive patients. a total of 320 eligible subjects will be recruited and randomization to two groups. the standard care group (n=160) will receive conventional hypertension treatment with baseline data collected.wearable blood pressure monitoring device management group (intervention group, n=160) will receive blood pressure monitoring remotely everyday and antihypertension medication treatment. primary outcome is net change in systolic blood pressure from baseline to 3 months follow-up. secondary outcomes include net change in diastolic blood pressure hypertension control ratio (bp \< 140/90 mmhg)


Eligibility criteria:
inclusion criteria: 1. aged more than 18 years old, less than or equal to 75 years old. 2. hypertensive patients (systolic/diastolic blood pressure ≥140/90 mmhg at two separate screening/baseline visits) 3. patients or guardians can skillfully use devices such as smartphones and electronic sphygmomanometers 4. voluntarily joined and signed the informed consent exclusion criteria: 1. pregnant women or women planning to become pregnant within the next year; 2. patients with secondary hypertension 3. patients with life expectancy less than 1 year 4. severe hepatic and renal insufficiency (alt \> 5 times ula, egfr \< 15ml/min/1.73mm2) 5. known active malignancy disease 6. the researcher believes that patients who are not suitable to participate in this study
pandemic influenza plasmid dna vaccines (needle)

Conditions: Influenza

Summary: the trial will enroll up to 57 subjects. qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. subjects will receive 2 vaccinations with a needle and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. the safety and immune system response will be studied throughout the trial.


Eligibility criteria:
inclusion criteria: * 18 to 45 years of age * able to provide informed consent and be followed for 6 months exclusion criteria: * no immunomodulatory therapy within the past 6 months * no evidence of immunodeficiency or pregnancy * no laboratory or evidence of clinically significant medical disease * no history of previous pdna immunization * no influenza immunization within the past 30 days * no blood donations within 30 days of screening visit * no history of bleeding disorder * no use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines

Keywords: pandemic influenza avian influenza dna vaccines antibody t cells ha/np/m2
identification and quantification of immune response induced by hyaluronidase and other factors of virulence of invasive human infections of streptococcus pneumoniae

Conditions: Invasive Pneumococcic

Summary: * 4 tubes (2 x7-ml dry tubes with yellow gelose, and 2 x 5 ml tubes with blue ctad) will be taken from the patient within 24 hours following inclusion (d0) in the department in which the patient is hospitalised * 4 tubes (2 x7-ml dry tubes with yellow gelose, and 2 x 5 ml tubes with blue ctad) will be taken from the patient every 7 days following inclusion for 5 weeks (if the patient is still in hospital at the time), in the department where he/she is hospitalised (d7, d14, d21, d28, d35). samples will no longer be taken once the patient has left the chu, even if all of the samples have not been taken. * for children less than 6 years old, only 2 tubes (1 x 7 ml dry tube with yellow gelose, and 1x5 ml tube with blue ctad) will be taken following the same timetable. * for hospitalised patients, a leeway of 48 hours is authorized for the sampling procedure. samples will be taken at the same time samples are taken for the usual care of the patient. * the tubes will be taken to the bacteriology laboratory using the usual collection circuit of the chu. these tubes will then be redirected to the infectious diseases laboratory to be centrifuged and then stored at -80°c. the strain of streptococcus pneumoniae isolated in the patient will be preserved at -80°c. if strains other than streptococcus pneumoniae are isolated, these different strains will all be preserved at -80°c under the same identification number.


Eligibility criteria:
inclusion criteria: * patients (children or adults) hospitalised at dijon chu * presenting invasive pneumococcal disease, confirmed by: the presence of streptococcus pneumoniae in a blood culture, or the presence of streptococcus pneumoniae in a sample of cerebrospinal fluid, or the presence of significant levels of streptococcus pneumoniae in an endobronchial sample (bronchial brushing or bronchoalveolar lavage), or in protected tracheal aspirations or in the spit of non-hospitalised patients or those in intensive care units. exclusion criteria: - patients in whom the implication of streptococcus pneumoniae is suspected because of: positive urinary soluble antigen of streptococcus pneumoniae with the exclusion of any other positive sample, presence of non- significant levels of streptococcus pneumoniae in bronchopulmonary samples the presence of significant levels of streptococcus pneumoniae in protected tracheal aspirations or in the spit, with the exclusion of any other positive sample in patients who had been in an intensive care unit for more than 48 hours at the time the sample was taken. - patients in whom streptococcus pneumoniae had already been isolated in the 5 weeks preceding inclusion in the present study.
clinical validation of novel malaria diagnostic tools for poc point-of-care testing

Conditions: Malaria; Diagnoses Disease; RDT

Summary: the aim of this study is to perform a performance evaluation of novel diagnostic tools for detecting malaria in malaria-endemic countries. at the beginning of 2022, find launched a call for innovation with the distinct aim to identify malaria innovations that have the potential to address the technical and operational limitations of current malaria rdts, particularly in view of the emergence of p. falciparum parasites with hrp2/3 deletions, the need for improved tools to identify all plasmodium species and/or the need for improved surveillance. this study will generate valuable data on the performance of these novel non-hrp2-based tests and inform find and developers on technical and operational assay optimization requirements for accelerated access of these tools to market.

this study aims to support product development efforts towards novel malaria diagnostics not hrp2-based by providing early-stage technology developers with valuable information on performance and basic feasibility data that can help to accelerate development. the who now recommends that where pfhrp2/3 gene deletions are reported (within countries or in neighboring countries), representative baseline surveys are to be conducted among suspected cases. if \>5% of false negative rdt results are attributed to these deletions, a change in rdt is necessary. plasmodium lactate dehydrogenase (pldh), appears as a good alternative to hrp2 as it is an essential protein expressed by all human-infecting plasmodium species. however, pldh-based rdts have shown to perform poorly at low parasitaemia, which is common among patients infected with p. vivax, p. malariae and p. ovale species as well as in asymptomatic infections. thus, rdts not based on hrp2 are limited; moreover, who prequalified ones that can detect and distinguish between plasmodium falciparum and plasmodium vivax are non-existent. the current malaria diagnostic landscape demands more innovation supporting and accelerating the development of new malaria diagnostic tools that that tackle these emerging issues.

Eligibility criteria:
inclusion criteria: * aged 5 years or older * presenting at the study site with symptoms and signs suggestive of malaria * freely agreeing to participate by signing an informed consent form (adults aged 18 and older and parent/legal guardian of a child) and providing assent (children aged 13-17) * willing to provide venous blood sample and other samples such as foot odour. exclusion criteria: * presence of symptoms and signs of severe disease and/or central nervous system infections, as defined by who guidelines participants are excluded from the foot odour collection if the following exclusion criteria apply: * skin lesions on the feet * infected skin on the feet * infected toenails

Keywords: malaria, diagnostics
cognitive status in chronic obstructive pulmonary disease's patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a chronic condition involving an impairment in functionality and in the execution of activities of daily life. the hypothesis of this study is to examine the relationship between cognitive status and clinical profile (respiratory, sleep quality, nutritional status) in patients with chronic obstructive pulmonary disease in two different moments: exacerbation or stable situation.

chronic obstructive pulmonary disease is a pathology with a systemic impact with a progressive evolution that is characterized by the presence of chronic airflow obstruction. patients with copd may have problems with cognitive functioning, either globally or in single cognitive domains, such as information processing, attention and concentration, memory, executive functioning and self-regulation. several studies have determined the prevalence of cognitive impairment in copd compared to healthy control subjects, reaching very high levels, 36% of copd patients with mild cognitive impairment compared with 12 % non- copd subjects.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic obstructive pulmonary disease with exacerbation or stable. * signed written consent. * medical approval for inclusion exclusion criteria: * heart disease. * neurological patients. * severe cognitive impairment in order not to complete the assessment.

Keywords: exacerbation cognitive chronic obstructive pulmonary disease
arena labs - improving clinician well being

Conditions: Mental Health Disorder

Summary: to determine the efficacy of the asynchronous performance coaching platform, arena strive at changing measures of physiological resilience, professional fulfillment, burnout, and self-valuation in full time clinicians.

this study is a prospective randomized controlled longitudinal crossover design with a per protocol analysis integrating one sensor (whoop, inc platform) and one educational intervention (arena strive platform). the whoop sensor collects data on heart rate (hr), heart rate variability (hrv), and sleep data, and will be worn by all participants in the experimental intervention. participants will be asked to wear the biometric sensor for 12 weeks but will have optional access to the device for a total of 24 weeks.

Eligibility criteria:
inclusion criteria: * employed full time by an atrium health affiliated entity * age 18+ * willing and able to give written informed consent for study participation * healthcare workers working ≥ 36 hours of clinical duties/week * willingness to wear whoop and keep it charged for the entire duration of study * have a smart phone for pairing with whoop and the arena strive platform exclusion criteria: * current diagnosis of a sleep-related breathing disorder including obstructive sleep apnea not being treated (with or without continuous positive airway pressure (cpap) treatment) * circadian rhythm sleep-wake disorders * narcolepsy * recurrent isolated sleep paralysis * restless legs syndrome * periodic leg movement disorder * comorbid nocturia or other conditions (benign prostatic hyperplasia) resulting in frequent need to get out of bed to use the bathroom during the night (≥3 times per night average) * atrial fibrillation * chronic obstructive pulmonary disease (copd) other than mild, pulmonary fibrosis or severe chronic lung disease * sleep apnea or undergoing treatment for a sleep related illness * lack of availability of iphone or android device

Keywords: professional fulfillment physiological resilience high-stress environment
improving outcomes in cleft palate surgery

Conditions: Cleft Palate

Summary: this is a pilot study to determine if an audit and feedback intervention decreases complication rates after cleft palate surgery.

this study will determine whether a surgeon-directed audit and feedback intervention reduces rates of oro-nasal fistula after cleft palate repair. fistula is an important potential complication of cleft palate repair. the study also evaluates feasibility of standardized outcome measurement in the care of children with cleft lip and palate, acceptability of standardized measurement, and acceptability of the audit and feedback intervention among surgeons. the results of this research will improve child health by enabling cleft surgeons to critically evaluate and improve their patient's outcomes.

Eligibility criteria:
inclusion criteria: active surgeon performing cleft palate repair in the us or canada. exclusion criteria: none
anti-reflux mucosal ablation therapy randomized sham control trial for gastroesophageal reflux disease

Conditions: Gastroesophageal Reflux Disease

Summary: the goal of this randomized clinical trial is to investigate the efficacy and safety of antireflux mucosal ablation (arma) for patients with refractory gastroesophageal reflux disease (gerd). the trial aim to evaluate : * efficacy of arma comparing with medical treatment alone (proton pump inhibitor (ppi)), using gerd-health related quality of life questionnaire (gerd- hrql questionnaire), improvement of acid exposure time and demeester score * safety and complications of arma participants will be randomly divided into 2 groups. the intervention group will be undergone arma, and the control group will be undergone sham endoscopic treatment. the primary endpoint will be symptoms relief (gerd-hrql decreases \> 50%). the secondary endpoint will be dosage adjustment of ppi, complications, improvement of acid exposure time and demeester score.


Eligibility criteria:
inclusion criteria: * adults aged over 18 years old * history of gerd for over 6 months, who had received ppis for over 6 months but still had symptoms of typical gerd symptoms (gerd-hrql score of \>8, acid reflux sensation or heartburn), and/or other symptoms as lump throat, night cough, acid related chest tightness (without other possible explanation of these symptoms) * acid exposure time \> 6% * demeester score ≥ 14.72 exclusion criteria: * pregnancy * bmi\>=35 * hiatal hernia \> 2cm or flap valve hill grade iii/iv * gerd la grade c/d or esophageal ulcer * abnormal anatomy of esophagus (esophagectomy, stricture, diverticulum) * barrett's esophagus with dysplasia * esophageal motility disorders * history of gastroparesis * cirrhosis * esophageal and gastric varices * previous gastric surgery and anti-reflux procedures * history of scleroderma or dermatomyositis * coagulation disorders (bleeding tendency and coagulopathy) * history of oncological disease (not active within 2 years)
reliability and validity of urdu translation of western ontario shoulder instability index

Conditions: Instability, Joint

Summary: the goal of this study is to translate western ontario shoulder instability index into urdu and test its authenticity and coherence among the pakistani community with shoulder instability. also check its correlation with disability of arm, shoulder, and hand questionnaire, rowe score , walch-duplay score and visual analogue scale.

the original english version of the western ontario shoulder instability index will be translated and culturally adapted .among shoulder instability population, western ontario shoulder instability index will provided to 90 participants which will be choose through convenience sampling technique . this sampling method based on pre-defined inclusion and exclusion criteria .to check intra-observer reliability of the final urdu translation of western ontario shoulder instability index, disability of arm, shoulder, and hand questionnaire, walch-duplay score, rowe score and visual analogue scale questionnaires will be filled at the same day by two observers for test inter-observers assessment second application will be applied after 35 minutes of first application. third assessment will be performed after seven days by first observer. data will be entered and analyzed by using statistical package of social sciences version 24 . internal consistency will be analyzed with cronbach's alpha value . intra-class correlation coefficient will be used to check retest reliability. urdu translation of western ontario shoulder instability index will be evaluated for content validity ,construct validity ,criterion validity and responsiveness.

Eligibility criteria:
inclusion criteria: * male and female both patients. * pursuing one or more incidences of dislocation, with or without surgical stabilization. * participants with glenohumeral joint instabilities. * patients between the ages of 20 and 60 who are interested in participating. exclusion criteria: * history or presence of ; * the presence of a disease other than the shoulder (osseous, tendinous, vascular, * inflammatory, radicular, muscular, and so on). * shoulder surgery except perhaps surgical stabilization. * the patient's unwillingness to engage in the study, as well as his or her lack of understanding or fill the questionnaires.

Keywords: western ontario shoulder instability index urdu version reliability validity shoulder instability walch-duplay score
tbtc study 23b:intensive pk of the nelfinavir rifabutin interaction in patients with hiv-tb

Conditions: HIV Infections; Tuberculosis

Summary: primary objective: to define the impact of nelfinavir (given at 1250mg bid as part of a combination antiretroviral regimen) on peak levels and area under the curve for rifabutin and the rifabutin metabolite, 25-o-desacetyl rifabutin when rifabutin is given at 300 mg bi-weekly as part of tuberculosis chemotherapy. secondary objectives: to compare the pharmacokinetics of nelfinavir given twice daily at 1250 mg bid with twice-weekly isoniazid and rifabutin to the pharmacokinetics of nelfinavir 1250 mg twice-daily in historical hiv-infected patients not receiving isoniazid and rifabutin. to evaluate the correlation between pharmacokinetic parameters of rifabutin and 25-o-desacetyl rifabutin and the occurrence of toxicity attributed to rifabutin in patients with hiv-related tuberculosis. to define detailed pharmacokinetics of isoniazid given at 15mg/kg or 900 mg in patients with hiv-related tuberculosis. to attempt to derive optimal sampling times for nelfinavir and rifabutin pharmacokinetic studies.


Eligibility criteria:
* patients with hiv-related tuberculosis

Keywords: tuberculosis tb
bone marrow stem cell mobilisation therapy for acute myocardial infarction (ami)(revival-2)

Conditions: Myocardial Infarction

Summary: the purpose of this study is to determine whether stem cell mobilization by granulocyte colony-stimulating factor (g-csf) therapy in patients with acute myocardial infarction after successful mechanical reperfusion reduces infarct size.

experimental studies and early-phase clinical trials suggest that transplantation of blood-derived or bone marrow-derived progenitor cells may improve cardiac regeneration after acute myocardial infarction. granulocyte colony-stimulating factor (g-csf) induces mobilization of bone marrow stem cells and, thereby, increases the number of circulating stem cells that are available cells for myocardial regeneration.

Eligibility criteria:
inclusion criteria: * st-elevation acute myocardial infarction (5 days before randomization) * successful percutaneous coronary intervention \[pci\] (performed within 12 hours from symptom onset) * scintigraphic infarct size \>5% of left ventricle * written informed consent exclusion criteria: * age \ 80 years * congestive heart failure defined as killip class \>2 * a history of myocardial infarction * electrical or hemodynamic instability * autoimmune diseases * fructose intolerance * malignancies * incompatibility of filgrastim * known or suspected pregnancy

Keywords: stem cells
phase 2 pilot study of the safety and efficacy of topical mw-iii in thermal burns

Conditions: Burns

Summary: to compare mw-iii to silvadene® cream 1% (silver sulfadiazine) with respect to "time to healing" (≥95% re-epithelialization) of a partial thickness target thermal burn.

this phase 2 pilot study will assess the safety and efficacy of topical mw-iii on thermal burns.

Eligibility criteria:
inclusion criteria: 1. adults, 18 years of age or older on the day of signing the informed consent. 2. thermal burns not exceeding a total body surface area (tbsa) of 25%, with at least one partial thickness burn of 0.5% tbsa or greater. if full thickness burn(s) are present at screening, the total full thickness burn area shall not exceed 10% tbsa. note: tbsa excludes areas of superficial (first degree) burns. 3. able and willing to give informed consent and comply with study procedures. exclusion criteria: 1. any burn that at screening is: 1. infected. 2. circumferential or deemed, in the judgment of the investigator, at high risk for developing compartment syndrome. 3. partial thickness that is likely, in the judgment of the investigator, to require grafting within 72 hours, or other non-protocol intervention. 2. severe inhalation injury or other significant non-burn trauma.

Keywords: burns, partial thickness burns
effects of muscle energy technique versus mobilization

Conditions: Sacroiliac Joint Dysfunction

Summary: the aim is to describe the severity of pain in postpartum female and management of sacroiliac joint pain and disability and define the effects of manual therapy on sacroiliac joint dysfunction and pain

the aim is to describe the severity of pain in postpartum female and management of sacroiliac joint pain and disability and define the effects of manual therapy on sacroiliac joint dysfunction and pain in postpartum females and to check whether the amount of gaining range of movement is similar among postpartum female undergoing with mobilization therapy and with muscle energy technique.

Eligibility criteria:
inclusion criteria: * 20-40 year having unilateral back pain around or on sacral sulcus, * positive posterior pain provocation test for sacroiliac joint dysfunction, * low back pain within six weeks of delivery * pain while sitting down, lying on the ipsilateral side of pain, or climbing stairs. * local tenderness of the posterior aspect of the sacroiliac joint * pain is usually localized over the buttock. * sharp, stabbing, and/or shooting pain which extends down the posterior thigh usually not past the knee. * c-section exclusion criteria: * neurological deficit * spinal tumors * scoliosis, * underwent spinal surgery and prolapsed * intervertebral disc with or without radiculopathy

Keywords: mobilization muscle energy technique postpartum sacroiliac joint pain